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Abstract
Background:  Secondary treatment of arteriosclerosis may be applicable for the primary
prevention of atherosclerosis in diabetic patients. This prospective, 2-year follow-up study was
designed to determine the efficacy and safety of antiplatelet therapy in the prevention of
atherosclerosis of diabetic subjects.
Methods: Patients with type 2 diabetes and arteriosclerosis obliterans from the Eastern Asian
countries were registered online and randomly assigned either to the aspirin group (81–100 mg/
day) or the cilostazol group (100–200 mg/day) in this international, 2-year, prospective follow-up
interventional study.
Results:  The primary study endpoint was changes in right and left maximum intima-media
thickness of the common carotid artery. Secondary endpoints include changes in right and left
maximum intima-media thickness of the internal carotid artery; semiquantitative evaluation of
cerebral infarction by magnetic resonance imaging; cardiovascular events including sudden death,
stroke, transient cerebral ischemic attacks, acute myocardial infarction, angina, and progression of
arteriosclerosis obliterans; overall death; withdrawal; and change in ankle-brachial pressure index.
Conclusion: This is the first study to use an online system that was developed in Asian countries
for pooling data from an international clinical trial. These findings are expected to help in the
prevention of diabetic atherosclerosis and subsequent cardiovascular and cerebrovascular disease.
Background
Westernization of lifestyle has led to an explosive increase
in the number of diabetic patients and an increase in dia-
betic atherosclerosis in Eastern Asian countries [1,2]. This
is of great concern for the future of patients and health sys-
tems in East Asia, and is a problem that requires immedi-
ate and careful evaluation. With this in mind a
cooperative, multinational research group in Japan,
Korea, China, and Phillippine has been formed to investi-
gate the potential for antiplatelet medication to prevent
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the occurrence and progression of diabetic atherosclerosis
in Asian patients.
The rationale for the study is based upon the finding that
the primary incidence rate of coronary artery disease
(CAD) in diabetic patients is similar to the secondary inci-
dence rate of CAD in nondiabetic patients. This finding
suggests that secondary treatment of atherosclerosis is
applicable to the primary prevention of arteriosclerosis in
diabetic patients. Antiplatelet drugs are widely reported to
be effective in preventing the recurrence of atherosclero-
sis. In one study [3], type 2 diabetic patients with early-
stage carotid atherosclerosis who were given aspirin
showed a slight progression of intima-media thickness
(IMT) of the carotid artery (0.033 ± 0.010 mm/year). In
another study [4], similar patients given cilostazol
showed negligible change in IMT (0.00 ± 0.16 mm/3
years). However, the primary preventive and secondary
therapeutic effects of these two drugs have not been suffi-
ciently investigated in the Asian diabetic patient popula-
tion. We therefore initiated an international, 2-year
prospective follow-up interventional study to clarify the
efficacy and usefulness of aspirin and cilostazol in the pri-
mary prevention and secondary treatment of diabetic
atherosclerosis in Asian patients. Assessment will be per-
formed by chronologically observing the intima-media
thickness (IMT) of the carotid artery, which is used as a
surrogate endpoint of atherosclerosis, and by analyzing
the occurrence and progression of large-vessel complica-
tions in patients with type 2 diabetes and mild atheroscle-
rosis [5,6].
Study design and protocol
The DAPC study has been registered on the University
Hospital Medical Information NetworkClinical Trials
Registry (UMIN-CTR) which is a non-profit organization
in Japan and meets the requirements of the International
Committee of Medical Journal Editors (ICMJE). Patients
enrolled in the study will have been dignosed with type 2
diabetes, aged between 40 to 85 years and with clinical
findings suggestive of arteriosclerosis obliterans (ASO)
(Table 1, Table 2). In the study ASO will be defined as
detection of the following findings in either of the
patient's lower limbs: an ABI (ankle brachial pressure
index) of <1.0 and a weakened or bilaterally different pul-
sation of the popliteal artery or dorsal artery of the foot; or
clinical signs and symptoms suggestive of ASO.
The following exclusion criteria were set: those with type
1 or secondary diabetes, severe ASO (greater than a Fon-
taine IIb category) or grade 4 or higher cerebral infarction
on the Modified Rankin Scale, and medical history of
angina or myocardial infarction. In addition, patients
with a range of concomitant comorbidities including
severe hepatic or renal dysfunction, congestive heart fail-
ure, bleeding disorders, or familial hypercholesterolemia,
those with allergy or hypersensitivity to the investiga-
tional drugs, pregnant or lactating women, or women
wishing to become pregnant, were excluded. Written
informed consent has been obtained from all patients,
and the study has been reviewed by the ethics review
board of the all institutes participated in this study if the
institute had the ethics review board.
Table 1: Enrollment Criteria
Inclusion criteria:
1) Type 2 diabetes mellitus
2) Age between 40 to 85 years
3) Clinical findings suggestive of arteriosclerosis obliterans (ASO)
Note 1: Definition of ASO: Patient who has the following lesions in either of the lower limbs
• ABI (ankle brachial pressure index) < 1.0
• A weakened or bilaterally different pulsation of popliteal artery or dorsal artery of foot
• clinical signs and symptoms suggestive of ASO
Exclusion criteria:
1) Type 1 diabetes mellitus or secondary diabetes mellitus
2) Age less than 40 or greater than 85 years
3) Severe ASO rated as Fontaine IIb or over
4) Cerebrovascular disorders rated as grade 4 or greater on the Modified Rankin Scale
5) Medical history of angina or myocardial infarction
6) Severe hepatic dysfunction (liver cirrhosis) or renal dysfunction (serum creatinine ≥ 1.5 mg/dL)
7) Congestive heart failure
8) Severe hematological abnormalities
9) Diagnosis of homologous familial hypercholesterolemia
10) Drug allergies or medical history of hypersensitivity to the investigational drugs
11) Pregnant or lactating women, or women who wish to become pregnant
12) Others whom the investigator judges inappropriate as subjects for this studyCardiovascular Diabetology 2006, 5:16 http://www.cardiab.com/content/5/1/16
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Registration of patients was preformed at the administra-
tion office of the Diabetic Atherosclerosis Prevention by
Cilostazol (DAPC) Study via the Internet, and once
enrolled, subjects were randomly assigned to the aspirin
group (81–100 mg/day; group A) or the cilostazol group
(100–200 mg/day; group C). Patients who were already
receiving antiplatelet drugs were assigned without a wash-
out period. The study period will be 2 years after the reg-
istration of subjects (registration period: November 2004
to March 2006; full study duration: December 2004 to
March 2008).
The primary study endpoint is the change in right and left
maximum IMT of the common carotid artery (CCA) and
mean IMT-CCA change. Secondary endpoints are the
change in right and left maximum IMT of the internal
carotid artery; semiquantitative evaluation of cerebral inf-
arction by MRI measurement; cardiovascular events
including sudden death, occurrence or recurrence of
stroke, transient cerebral ischemic attacks, acute myocar-
dial infarction, angina, and progression of ASO; overall
death; withdrawal; and change in ABI.
Investigations will be performed at the start of the study,
after 1 year, at the conclusion of the study, and at the time
of any discontinuations or changes in dosage. Any adverse
reactions will also be assessed.
Appendix: DAPC Study Participating Institutions and Investigators
Investigator Institution
Japan
Goto T Department of Internal Medicine, Japanese Red Cross Akita Hospital, Akita
Imano A Department of Internal Medicine, Osaka Kouseinenkin Hospital, Osaka, Japan
Jinnouchi H Department of Internal Medicine, Jinnouchi Hospital, Kumamoto, Japan
Kanazawa A Department of Internal Medicine, Division of Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, 
Japan
Kasayama S Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
Kosugi K Department of Internal Medicine, Osaka Police Hospital, Osaka, Japan
Matsuoka T Kurashiki Life Style Disease Center, Okayama, Japan
Nakato T Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan
Ono T Department of Diabetes and Endocrine, Iwaki Kyoritsu Hospital, Fukushima, Japan
Ota M Department of Comprehensive Medical Care, Ota Nishinouchi Hospital, Fukushima
Seino H Center of Diabetes, Ota Nishinouchi Hospital, Fukushima, Japan
Sumiya T Department of Endocrine and Diabetes, NTT West Osaka Hospital, Osaka, Japan
Yagi M Department of Endocrinology and Metabolism, Belland General Hospital, Osaka, Japan
Yamasaki Y* Department of Endocrine and Metabolic Internal Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
Korea
Chung MY Department of Internal Medicine, Chonnam National University College of Medicine, Gwangju, Korea
Kim YS* Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea
Lee HC Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Soon KH Department of Internal Medicine, Keimyung University College of Medicine, Daegu, Korea
Yoon KH Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea
Philippines
Ganzon MS Department of Vascular Medicine, Heart Institute, St. Luke’s Medical Center, Manila, Philippines
China
Guo X Department of Endocrinology, Peking University First Hospital, Beijing, China
*Study director
Table 2: Study Outline
Target number of patients: 408 patients
Study Design: Randomization Aspirin group (81–100 mg/day; Group A)
Cilostazol group (100–200 mg/day; Group C)
Follow-up: 2-year prospective follow-up study
Primary endpoints:
IMT*: Variation of right and left max IMT-CCA and mean IMT-CCA
Secondary endpoints:
IMT*: Variation of right and left max IMT-ICA
*Variation is measured by the IMT Evaluation Committee by using a diagnostic software application called IntimaScope® while the allocations are 
blinded.Cardiovascular Diabetology 2006, 5:16 http://www.cardiab.com/content/5/1/16
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Statistical analysis using changes in IMT was first under-
taken to determine the number of patients required to
identify a significant difference between the two groups.
As a result, at least 408 patients were calculated to be
required to obtain a significant difference (p  < 0.05)
between the two groups. Therefore, the target number of
patients was 400 for the 1-year registration period. Statis-
tical analysis will be performed using the t-test to compare
the change in maximum IMT, the log-rank test for inci-
dence of events and mortality rate, and the Kaplan-Meier
method to plot survival curves. Ratios of events between
the 2 groups and confidence intervals are to be deter-
mined by Cox regression. A 1-way ANOVA will be used to
compare ABI. The administrative office of the DAPC Study
will analyze these data.
Discussion
The aim of this study is to clarify the efficacy and useful-
ness of two different antiplatelet drugs, aspirin and
cilostazol, in the prevention of occurrence or progression
of atherosclerosis in patients with type 2 diabetes.
Antiplatelet drugs such as aspirin have been shown to be
effective in preventing the recurrence of atherosclerosis in
these patients. However, effectiveness of aspirin on dia-
betic patients is still controversial. Kodama and colleagues
[3] have reported that both aspirin and ticlopidine signif-
icantly reduced, but did not halt, progression of increase
in IMT in patients with type 2 diabetes and early-stage
carotid atherosclerosis. Recently, the Primary Prevention
Project (PPP) Trial showed that a significant reduction of
the total cardiovascular events was observed in nondia-
betic subjects but no significant reduction was observed in
diabetic subjects [7]. In contrast, Shinoda-Tagawa and col-
leagues [4] showed that similar patients given cilostazol
showed a negligible change in IMT over a 3-year follow-
up period. Cilostazol is also shown to be effective in
reducing occurrence of cerebral infarction in diabetic sub-
jects [4]. We feel that the therapeutic effects resulting from
the differing mechanisms of action of aspirin and cilosta-
zol have not been sufficiently investigated in this patient
population.
The results of this study are expected to assist in the devel-
opment of appropriate drug therapies for patients with
type 2 diabetes and atherosclerosis. This is a very impor-
tant objective because the incidence of this common com-
plication of diabetes is rising at a staggering rate among
many Asian countries. It is expected that health systems in
Asia will be severely stretched in the near future by trying
to manage patients with diabetic complications, and the
economic and social costs to the individuals and countries
will be large. The design of this study is ground breaking
in that enrollment was via the Internet and all results will
be pooled by using a unique online patient registry sys-
tem. Not only are all of the mathematical and demo-
graphic data to be held on this database, but also all of the
images taken from the MRI assessment of cerebral changes
and alterations in IMT. This is the first such online system
to be developed in Asian countries for pooling data from
an international clinical trial. Results will be available rap-
idly, and these findings are expected to provide clinical
data that will help in the prevention of diabetic athero-
sclerosis and subsequent cardiovascular and cerebrovas-
cular disease. Results from this important clinical trial are
planned to be published in 2008.
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